SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]
SEC Accession No. 0001213900-24-034940
Filing Date
2024-04-22
Accepted
2024-04-22 16:31:21
Documents
161
Period of Report
2023-12-31

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO FORM 20-F ea0204302-20fa1_altamira.htm   iXBRL 20-F/A 2797490
2 CERTIFICATION ea020430201ex12-1_altamira.htm EX-12.1 9365
3 CERTIFICATION ea020430201ex12-2_altamira.htm EX-12.2 8767
4 CERTIFICATION ea020430201ex13-1_altamira.htm EX-13.1 3891
5 CERTIFICATION ea020430201ex13-2_altamira.htm EX-13.2 3681
  Complete submission text file 0001213900-24-034940.txt   14098732

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE cyto-20231231.xsd EX-101.SCH 201566
7 XBRL CALCULATION FILE cyto-20231231_cal.xml EX-101.CAL 63914
8 XBRL DEFINITION FILE cyto-20231231_def.xml EX-101.DEF 570007
9 XBRL LABEL FILE cyto-20231231_lab.xml EX-101.LAB 1135515
10 XBRL PRESENTATION FILE cyto-20231231_pre.xml EX-101.PRE 596302
165 EXTRACTED XBRL INSTANCE DOCUMENT ea0204302-20fa1_altamira_htm.xml XML 2575976
Mailing Address CLARENDON HOUSE 2 CHURCH STREET HAMILTON HM 11 D0 00000
Business Address CLARENDON HOUSE 2 CHURCH STREET HAMILTON HM 11 D0 00000 41 (0) 41 729 71 94
Altamira Therapeutics Ltd. (Filer) CIK: 0001601936 (see all company filings)

IRS No.: 000000000 | State of Incorp.: D0 | Fiscal Year End: 1231
Type: 20-F/A | Act: 34 | File No.: 001-36582 | Film No.: 24861572
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)